Want to join the conversation?
$AGN's Namenda XR revenues for 1Q16 were $173MM, as prescriptions and formulary coverage remained stable following the loss of exclusivity of Namenda IR. Lumigan/Ganfort revenues were $170MM reflecting stable performance across its glaucoma product franchise. Bystolic revenues remained stable at $164MM.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)